Osteoporosis is a disease that affects millions of individuals in the United States and
abroad. It leads to decreased bone mass and causes an increased risk of fracture. This study
will compare continuous versus cyclic treatment with teriparatide combined with alendronate,
another drug for osteoporosis, or teriparatide alone in women with osteoporosis.
Phase:
Phase 2
Details
Lead Sponsor:
Helen Hayes Hospital
Collaborators:
Health Research, Inc. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Treatments:
Alendronate Calcium Calcium, Dietary Cholecalciferol Ergocalciferols Teriparatide Vitamin D Vitamins